Fennec Pharmaceuticals Inc. (FENC)

USD 5.66

(-6.75%)

Market Cap (In USD)

155.24 Million

Revenue (In USD)

21.25 Million

Net Income (In USD)

-16.04 Million

Avg. Volume

96.88 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.96-11.92
PE
-
EPS
-
Beta Value
0.267
ISIN
CA31447P1009
CUSIP
31447P100
CIK
1211583
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Rostislav Raykov
Employee Count
-
Website
https://www.fennecpharma.com
Ipo Date
2017-09-15
Details
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.